A. Flor

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

K. Patra, V. Hsu, B. White, 2016, Arthritis Research & Therapy.

Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty.

J. Baron, G. Cutler, K. Barnes, 2004, The Journal of clinical endocrinology and metabolism.

Symptoms and Association with Health Outcomes in Relapsing-Remitting Multiple Sclerosis: Results of a US Patient Survey

J. Vietri, Angela E. Williams, G. Isherwood, 2014, Multiple sclerosis international.

Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin‐releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty

G. Cutler, K. Barnes, E. Leschek, 2017, The Journal of pediatrics.

Challenges and opportunities in designing clinical trials for neuromyelitis optica

J. M. Behne, Terry J. Smith, M. Sormani, 2015, Neurology.

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

K. Patra, M. Agius, M. Maciejowski, 2017, Multiple sclerosis.

Placebo-controlled study in neuromyelitis optica—Ethical and design considerations

Jeffrey A. Cohen, K. Patra, F. Paul, 2015, Multiple sclerosis.

Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study

L. Hansen, Marcella Petrone, T. Hoang, 2023, Clinical Pharmacokinetics.